AMEX · AIM
Healthcare · Biotechnology
$0.25
Up+$0.01 (+2.09%)
Updated Aug 21, 2026, 9:14 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
AIM closed at $0.25 after 21 trading sessions, up 1.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $0.2431 | $0.2589 | $0.2389 | $0.2531 | 590.08K |
| Aug 19, 2026 | $0.2398 | $0.2591 | $0.2382 | $0.2382 | 1.16M |
| Aug 18, 2026 | $0.2435 | $0.256 | $0.2339 | $0.2339 | 459.68K |
| Aug 17, 2026 | $0.2304 | $0.258 | $0.2262 | $0.243 | 2.11M |
| Aug 14, 2026 | $0.25 | $0.2597 | $0.1901 | $0.2199 | 1.85M |
| Aug 13, 2026 | $0.259 | $0.2623 | $0.2549 | $0.2586 | 426.9K |
| Aug 12, 2026 | $0.2541 | $0.2627 | $0.2461 | $0.257 | 874.91K |
| Aug 11, 2026 | $0.26 | $0.2627 | $0.246 | $0.2547 | 1.55M |
| Aug 10, 2026 | $0.264 | $0.28 | $0.26 | $0.263 | 1.87M |
| Aug 7, 2026 | $0.264 | $0.29 | $0.261 | $0.2854 | 1.06M |
| Aug 6, 2026 | $0.2851 | $0.30 | $0.265 | $0.2708 | 3.58M |
| Aug 5, 2026 | $0.2629 | $0.30 | $0.2511 | $0.2836 | 6.21M |
| Aug 4, 2026 | $0.27 | $0.27 | $0.2429 | $0.263 | 1.27M |
| Aug 3, 2026 | $0.2693 | $0.27 | $0.2524 | $0.264 | 1.93M |
| Jul 31, 2026 | $0.244 | $0.275 | $0.24 | $0.2536 | 3.65M |
| Jul 30, 2026 | $0.238 | $0.2449 | $0.2346 | $0.235 | 376.59K |
| Jul 29, 2026 | $0.2408 | $0.245 | $0.2339 | $0.24 | 370.75K |
| Jul 28, 2026 | $0.2442 | $0.2499 | $0.2331 | $0.236 | 581.01K |
| Jul 27, 2026 | $0.25 | $0.2574 | $0.2402 | $0.25 | 343.74K |
| Jul 24, 2026 | $0.2397 | $0.2546 | $0.2395 | $0.249 | 270.87K |
| Jul 23, 2026 | $0.26 | $0.26 | $0.238 | $0.25 | 475.38K |
The latest Smart Investors Daily articles mentioning AIM.
AIM research
Company profile and research snapshot.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Ascendiant Capital | Buy | — |
| Jun 1, 2026 | Ascendiant Capital | Buy | — |
| Apr 10, 2026 | Ascendiant Capital | Buy | — |
| Dec 8, 2025 | Ascendiant Capital | Buy | — |
| Oct 3, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 27, 2026
AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of
Benzinga · Feb 25, 2026
Benzinga · Feb 23, 2026
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined
Benzinga · Feb 11, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AIM.
